Mullins, C Daniel <br/><br/>
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.  [electronic resource] 

 -  Schizophrenia research  Jan 2008 
 - 8-15 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0920-9964 
<br/><br/><label>Standard No.: </label>10.1016/j.schres.2007.04.035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antipsychotic Agents--adverse effects<br/>Aripiprazole<br/>Dibenzothiazepines--adverse effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Patient Readmission--statistics & numerical data<br/>Piperazines--adverse effects<br/>Proportional Hazards Models<br/>Quetiapine Fumarate<br/>Quinolones--adverse effects<br/>Randomized Controlled Trials as Topic--statistics & numerical data<br/>Risk Factors<br/>Risperidone--adverse effects<br/>Schizophrenia--diagnosis<br/>Schizophrenia, Paranoid--diagnosis<br/>Schizophrenic Psychology<br/>Sensitivity and Specificity<br/>Substance Withdrawal Syndrome--epidemiology<br/>Survival Rate<br/>Thiazoles--adverse effects